Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer

Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer is a phase 1/2, interventional study registered as NCT07665684 by University Health Network, Toronto, with a registry enrolment figure of 67 participants, started 2026-07 and due to reach its primary completion in 2029-05. Interventions recorded: Samuraciclib + Gemcitabine & Nab-Paclitaxel. Conditions listed: Pancreas Ductal Adenocarcinoma; Pancreas Cancer, Metastatic; Pancreatic Adenocarcinoma Metastatic; Adenosquamous Carcinoma of the Pancreas; Mucinous Adenocarcinoma. Primary outcome: Frequencies of adverse events (AEs), as graded by CTCAE v6.0 and reported by dose level; Percentages of adverse events (AEs), as graded by CTCAE v6.0 and reported by dose level; Frequencies of dose-limiting toxicities reported by dose level. Pancreatic eligibility wording from the registry: "Known homologous recombination deficient pancreatic cancer, including germline or somatic BRCA1/2 or PALB2 mutations". Sites: Canada. No results are recorded here; the registry entry is the source.